Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mayne Pharma Group ( (AU:MYX) ) has issued an announcement.
Mayne Pharma Group, an ASX-listed specialty pharmaceutical company, focuses on innovative oral drug delivery systems and commercialises dermatology and women’s health products, particularly in the U.S. market. It also offers global contract development and manufacturing services, underpinned by four decades of experience bringing new formulations to market.
The company announced that CEO Aaron Gray will present at the ASX SMIDcaps Conference in Sydney on 25 March 2026, highlighting recent progress in women’s health and dermatology. The presentation will also cover the rollout of the DistributeRx platform, which aims to improve prescription-to-patient access and signals the company’s strategic priorities for the remainder of 2026.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an ASX-listed specialty pharmaceutical company focused on commercialising novel medicines that improve safety and accessibility for patients. The company is a leader in dermatology and women’s health in the United States, and it also provides contract development and manufacturing services globally, leveraging a 40-year track record in oral drug delivery innovation.
Average Trading Volume: 523,098
Technical Sentiment Signal: Sell
Current Market Cap: A$180.4M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.